Melissa Badowski, PharmD, MPH, FCCP, FIDSA, BCIDP, BCPS, AAHIVP
Clinical Associate Professor
Section of Infectious Diseases Pharmacotherapy
Department of Pharmacy Practice
University of Illinois at Chicago, College of Pharmacy
Shauna Applin, A-NP, AAHIVs
HIV Clinical Director
Adult Medicine Lead Provider
Community Health Care
Hilltop Regional Medical Center
This comprehensive electronic/downloadable monograph has been developed to specifically support the needs of pharmacists now challenged to come up to speed on guidelines and protocols for HIV preexposure and postexposure prophylaxis (PrEP and PEP). A number of states in the United States have expanded the pharmacy scope of practice and this continuing education activity will provide the necessary clinical information for initiating and monitoring PrEP and PEP treatment in a pharmacy setting. In December 2021, the Centers for Disease Control and Prevention (CDC) released the 2021 Updated PrEP Clinical Practice Guidelines, and pharmacists now need to be trained to incorporate these updated guidelines into their daily practice. Providing 2.0 contact hour(s) (0.20 CEUs) from the Accreditation Council for Pharmacy Education, this monograph addresses all content to fulfill most state Board of Pharmacy training requirements for pharmacists wishing to become PrEP and PEP providers, such as:
Pharmacology, safety, and efficacy of HIV medications used for PEP and PrEP (including oral tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC), oral tenofovir alafenamide (TAF)/FTC, and long-acting injectable cabotegravir)
Assessment of sexual health and HIV risk
Screening for HIV and sexually transmitted infections (STIs), and laboratory testing to determine PrEP/PEP eligibility
2021 CDC Updated PrEP Clinical Practice Guidelines for PrEP eligibility, prescribing, and management
Clinical practice guidelines for PEP eligibility, prescribing, and management
If you are a pharmacist practicing in Nevada, Oregon or Virginia, consider the state primer CE activity for your state as well.
The educational design of this monograph addresses the needs of clinical and community pharmacists involved in the treatment of patients at risk for HIV infection as well as managed care pharmacists, pharmacy benefit managers, and specialty pharmacists.
After completing this activity, participants will be better prepared to:
Describe the legal and professional parameters that allow for pharmacist-led or pharmacy-based direct delivery of postexposure prophylaxis (PEP) and preexposure prophylaxis (PrEP) services
Assess patient’s risk of HIV acquisition based on the type of exposure
Determine patients’ PEP/PrEP eligibility through HIV testing, sexual history-taking, and appropriate laboratory testing
Implement guideline-driven PEP/PrEP-prescribing principles regarding treatment initiation, monitoring, and referral
Identify infrastructure needs for in-pharmacy implementation of a PEP/PrEP prescribing initiative
Pharmacist Accreditation Statement
Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
Global Education Group designates this continuing education activity for 2.0 contact hour(s) (0.20 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number 0530-9999-22-063-H02-P)
This is a knowledge-based activity.
Disclosure of Conflicts of Interest
Global Education Group adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the ACCME and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Melissa Badowski, PharmD - Nothing to disclose.
Shauna Applin, A-NP, AAHIVs - Consulting Fee: Gilead, Janssen, Merck; Contracted Research: Gilead (PI); Speakers’ Bureau: Gilead, Merck
The planners and managers have the following relevant financial relationships with ineligible companies:
Lindsay Borvansky: Nothing to disclose
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Ashley Cann: Nothing to disclose
Stacey Ullman, MHS: Nothing to disclose
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group and Integritas Communications do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Instructions to Receive Credit
In order to received credit, participants must complete the following:
- Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
- Complete the Preactivity Questions.
- Review the activity content.
- Achieve a grade of 70% on the Postactivity Test Questions and complete the Evaluation.
- CE credits will be uplaoded to CPE Monitor within 60 days of completion.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Global Education Group Contact Information
For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or firstname.lastname@example.org.